MA47816A - Composition pharmaceutique comprenant du sélexipag - Google Patents

Composition pharmaceutique comprenant du sélexipag

Info

Publication number
MA47816A
MA47816A MA047816A MA47816A MA47816A MA 47816 A MA47816 A MA 47816A MA 047816 A MA047816 A MA 047816A MA 47816 A MA47816 A MA 47816A MA 47816 A MA47816 A MA 47816A
Authority
MA
Morocco
Prior art keywords
selexipag
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA047816A
Other languages
English (en)
Inventor
Klaus Hellerbrand
Alexandra Schlicker-Spain
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA47816A publication Critical patent/MA47816A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047816A 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag MA47816A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08

Publications (1)

Publication Number Publication Date
MA47816A true MA47816A (fr) 2020-01-15

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047816A MA47816A (fr) 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag

Country Status (27)

Country Link
US (1) US20200129506A1 (fr)
EP (1) EP3592391B1 (fr)
JP (1) JP6964679B2 (fr)
KR (1) KR102593075B1 (fr)
CN (1) CN110430900B (fr)
AR (1) AR111570A1 (fr)
AU (1) AU2018229750B2 (fr)
BR (1) BR112019018420A2 (fr)
CA (1) CA3055010A1 (fr)
CL (1) CL2019002511A1 (fr)
CO (1) CO2019009221A2 (fr)
CR (1) CR20190455A (fr)
DO (1) DOP2019000250A (fr)
EA (1) EA201992074A1 (fr)
EC (1) ECSP19072294A (fr)
ES (1) ES2880009T3 (fr)
IL (1) IL269061A (fr)
JO (1) JOP20190204A1 (fr)
MA (1) MA47816A (fr)
MX (1) MX2019010598A (fr)
NI (1) NI201900090A (fr)
PE (1) PE20191492A1 (fr)
PH (1) PH12019502033A1 (fr)
PL (1) PL3592391T3 (fr)
SG (1) SG11201907804QA (fr)
TW (1) TWI764996B (fr)
WO (1) WO2018162527A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
JP2022536623A (ja) * 2019-06-11 2022-08-18 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
PE20221455A1 (es) * 2019-10-23 2022-09-21 Actelion Pharmaceuticals Ltd Composicion farmaceutica que comprende selexipag
WO2021152060A1 (fr) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Composition de sélexipag à libération contrôlée
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (fr) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Composition lyophilisée comprenant du sélexipag
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023209731A1 (fr) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Formes posologiques injectables liquides ou lyophilisées de sélexipag et leur procédé de préparation
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
WO2023238952A1 (fr) * 2022-06-10 2023-12-14 日本新薬株式会社 Composition pharmaceutique
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (fr) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
ES2307905T3 (es) * 2002-02-22 2008-12-01 Schering Corporation Formulaciones farmaceuticas de agentes antineoplasicos, en particular temozolomida, procedimientos de obtencion y de uso.
MX2010008745A (es) 2008-02-28 2010-08-30 Nippon Shinyaku Co Ltd Inhibidor de fibrosis.
WO2009154246A1 (fr) 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
CA2728161C (fr) 2008-06-23 2017-06-06 Nippon Shinyaku Co., Ltd. Agent therapeutique pour une affection abdominale inflammatoire
WO2009157397A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
CN102065863A (zh) 2008-06-23 2011-05-18 日本新药株式会社 椎管狭窄症治疗剂
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (fr) 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
US20140044797A1 (en) * 2011-04-19 2014-02-13 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
WO2013024051A1 (fr) * 2011-08-12 2013-02-21 Ascendis Pharma A/S Composition à libération prolongée de prostacycline
ES2733998T3 (es) * 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9925263B2 (en) * 2013-09-11 2018-03-27 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising procaine and uses thereof
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (fr) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Procédés de préparation de selexipag et de sa forme amorphe
EP3192502A1 (fr) * 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag

Also Published As

Publication number Publication date
CN110430900A (zh) 2019-11-08
SG11201907804QA (en) 2019-09-27
MX2019010598A (es) 2019-10-15
CO2019009221A2 (es) 2019-08-30
PL3592391T3 (pl) 2021-11-02
EP3592391B1 (fr) 2021-04-21
PE20191492A1 (es) 2019-10-21
AU2018229750A1 (en) 2019-09-12
CL2019002511A1 (es) 2020-01-17
DOP2019000250A (es) 2020-09-15
CA3055010A1 (fr) 2018-09-13
ECSP19072294A (es) 2019-11-30
JP6964679B2 (ja) 2021-11-10
PH12019502033A1 (en) 2020-06-15
CN110430900B (zh) 2023-09-19
KR20190122803A (ko) 2019-10-30
NI201900090A (es) 2020-03-11
EP3592391A1 (fr) 2020-01-15
EA201992074A1 (ru) 2020-02-27
AR111570A1 (es) 2019-07-31
CR20190455A (es) 2019-11-12
BR112019018420A2 (pt) 2020-04-14
KR102593075B1 (ko) 2023-10-23
TW201842910A (zh) 2018-12-16
JOP20190204A1 (ar) 2019-09-05
ES2880009T3 (es) 2021-11-23
TWI764996B (zh) 2022-05-21
US20200129506A1 (en) 2020-04-30
JP2020509070A (ja) 2020-03-26
IL269061A (en) 2019-11-28
WO2018162527A1 (fr) 2018-09-13
AU2018229750B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
KR102281667B9 (ko) 아트로핀 약학 조성물 (atropine pharmaceutical compositions)
DK3529248T3 (da) Farmaceutiske sammensætninger
MA46334A (fr) Composition pharmaceutique liquide
MA49726A (fr) Formulation d'anticorps anti-cgrp
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
DK3532029T3 (da) Flydende farmaceutisk sammensætning
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
DK3634377T3 (da) Farmaceutisk formulering
MA43705A (fr) Formulation pharmaceutique
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
MA47516A (fr) Composition pharmaceutique
DK3348260T3 (da) Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
MA49837A (fr) Compositions pharmaceutiques
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
MA40982A (fr) Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA52704A (fr) Préparation pharmaceutique
DK3400017T3 (da) Kontinuerlig kompleksering af aktive farmaceutiske ingredienser
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3601277T3 (da) Farmaceutisk formulering
MA45126A (fr) Formulation pharmaceutique antifongique